Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug

Arcus Biosciences, Inc. (NYSE:RCUS) on Friday announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc. (NASDAQ:GILD) , due to futility. • Arcus Biosciences stock is among today’s weakest performers. Why is RCUS stock dropping?The decision is based on the recommendation from the Independent Data Monitoring Committee (IDMC) following its review of data from an event-driven, pre-specified interim analysis of overall survival (OS).STAR-221 evaluated ...